{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:57:04Z","timestamp":1787169424097,"version":"build-2736575974"},"reference-count":18,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"unspecified","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,6,15]]},"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>\n                    A patient on a regimen of idelalisib and corticosteroids for a relapse of follicular lymphoma presented to our emergency ward with a fever of unknown origin. Despite the initiation of broad-spectrum antibiotics and fluids, the patient\u2019s clinical condition deteriorated. Eventually, a diagnosis of disseminated cryptococcosis was established and immunophenotyping revealed complete absence of circulating B and CD4\n                    <jats:sup>+<\/jats:sup>\n                    -T lymphocytes, and a markedly diminished CD8\n                    <jats:sup>+<\/jats:sup>\n                    -T lymphocyte count. In this case, treatment with idelalisib and corticosteroids likely resulted in profound lymphopenia and the first reported instance of disseminated cryptococcosis under this regimen. After the withdrawal of idelalisib and steroids and initiation of antifungal therapy, lymphocyte counts partially recovered. After clinical improvement, the patient could be discharged from the hospital. This case highlights that the combination of idelalisib and corticosteroids can cause significant immunocompromise and opportunistic infections. Additionally, we illustrate the rate of lymphocyte reconstitution after withdrawal from idelalisib and corticosteroids.\n                  <\/jats:p>","DOI":"10.1136\/bcr-2020-235216","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T02:04:35Z","timestamp":1594001075000},"page":"e235216","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Disseminated cryptococcal disease during treatment with idelalisib and corticosteroids for follicular lymphoma"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0070-138X","authenticated-orcid":false,"given":"Paul J","family":"Hengeveld","sequence":"first","affiliation":[{"name":"Immunology, Erasmus MC, Rotterdam, The Netherlands"},{"name":"Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7316-029X","authenticated-orcid":false,"given":"Eva","family":"de Jongh","sequence":"additional","affiliation":[{"name":"Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0746-7039","authenticated-orcid":false,"given":"Peter E","family":"Westerweel","sequence":"additional","affiliation":[{"name":"Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-3547","authenticated-orcid":false,"given":"Mark-David","family":"Levin","sequence":"additional","affiliation":[{"name":"Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,7,5]]},"reference":[{"key":"2025082800413168000_13.7.e235216.1","unstructured":"Howlader N , Noone A , Krapcho M , et al . Seer cancer statistics review, 1975-2016. Bethesda, MD: National Cancer Institute, 2019. https:\/\/seer.cancer.gov\/csr\/1975_2016\/"},{"key":"2025082800413168000_13.7.e235216.2","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1080\/10428194.2018.1508666","article-title":"Cryptococcus neoformans infections in patients with lymphoproliferative neoplasms","volume":"60","author":"Dioverti","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"2025082800413168000_13.7.e235216.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2004.12.004"},{"key":"2025082800413168000_13.7.e235216.4","doi-asserted-by":"publisher","DOI":"10.1086\/649858"},{"key":"2025082800413168000_13.7.e235216.5","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328322ffac"},{"key":"2025082800413168000_13.7.e235216.6","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12496"},{"key":"2025082800413168000_13.7.e235216.7","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/myc.13001","article-title":"Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: an observational study","volume":"62","author":"Ruchlemer","year":"2019","journal-title":"Mycoses"},{"key":"2025082800413168000_13.7.e235216.8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix687"},{"key":"2025082800413168000_13.7.e235216.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"2025082800413168000_13.7.e235216.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"2025082800413168000_13.7.e235216.11","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41375-019-0388-x","article-title":"Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European conference on infections in leukemia (ECIL)","volume":"33","author":"Maschmeyer","year":"2019","journal-title":"Leukemia"},{"key":"2025082800413168000_13.7.e235216.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-232330"},{"key":"2025082800413168000_13.7.e235216.13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701703"},{"key":"2025082800413168000_13.7.e235216.14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.187070"},{"key":"2025082800413168000_13.7.e235216.15","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)","volume":"24 Suppl 2","author":"Reinwald","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2025082800413168000_13.7.e235216.16","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-84-3-304"},{"key":"2025082800413168000_13.7.e235216.17","first-page":"625","article-title":"Effect of corticosteroids on the human immune response: comparison of one and three daily 1 GM intravenous pulses of methylprednisolone","volume":"91","author":"Fan","year":"1978","journal-title":"J Lab Clin Med"},{"key":"2025082800413168000_13.7.e235216.18","doi-asserted-by":"publisher","DOI":"10.1086\/322597"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-235216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:41:40Z","timestamp":1756366900000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-235216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":18,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7,5]]},"published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1136\/bcr-2020-235216"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-235216","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}